ClinicalTrials.gg
CompletedNCT01078298Updated Apr 16, 2013Results posted

Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression

A Phase 4 interventional study of varenicline and placebo in Smoking Cessation and Depression, sponsored by Pfizer. Completed at 41 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-04-16.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
27th of 110
525 · median 209
Started
2010
with 6 others
Phase 4
47 of 110
3 open now
Registered
47th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 27th largest by enrollment, is one of 7 that started in 2010, is one of 47 in phase 4, and was the 47th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.

03

Conditions studied

  • Smoking Cessation
  • Depression

Keywords

  • smoking
  • smoking cessation
  • smoking cessation in depressed subjects
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cigarette smokers, 18-75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt
  • Smoked an average of at least 10 cigarettes per day during past year and over past month, and exhaled carbon monoxide (CO) > 10 ppm at screening
  • Current or past diagnosis of MDD without psychotic features, either single or recurrent, using DSM IV TR based on clinical assessment and confirmed by SCID and at least one of the following:
  • On stable antidepressant treatment for MDD (stable dose for at least 2 months)
  • Major depressive episode, using DSM IV TR, in the past 2 years successfully treated

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of dementia, schizophrenia, schizoaffective disorder, or other psychotic disorder, bipolar I disorder, bipolar II disorder.
  • Subjects with antisocial, schizotypal, or any other personality disorder severe enough to compromise the subject's ability to comply with the study requirements..
  • Current use of either bupropion or nortryptiline.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
525 participants (actual)

Study arms

  • Experimental
    varenicline

    Drug: varenicline

  • Placebo comparator
    placebo

    placebo

    Drug: placebo

Interventions

  • varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks

    Also known as: Champix/Chantix

  • Drugplacebo

    placebo tablets matched in appearance and dosage to varenicline tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Four-Week Continuous Quit Rate (CQR)

    Percentage of participants who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) questions: 'Has the participant smoked cigarettes' and 'Has the participant used other nicotine-containing products' in the last 7 days (Week 9) or since last study visit (Week 9 through 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm).

    Time frame: Week 9 through Week 12

Secondary outcomes

  1. Percentage of Participants With Continuous Abstinence Rate (CAR)

    Percentage of participants who remained abstinent from the period defined as start of the primary endpoint (Week 9) through Week 24 and the end of follow-up (Week 52) by reporting no use of nicotine-containing products confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

    Time frame: Week 9 through Week 24, Week 9 through Week 52

  2. Number of Participants With 7-day Point Prevalence (PP) of Abstinence

    Number of participants reporting no use of nicotine-containing products in the last 7 days confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

    Time frame: Weeks 12, 24, 52

  3. Number of Participants With 4-Week Point Prevalence (PP) of Abstinence

    Number of participants at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

    Time frame: Week 52

Other outcomes

  1. Number of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events)

    Adverse Event (AE):any untoward medical occurrence attributed to study drug in participant who received study drug.SAE:AE causing:death;initial/prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying);persistent/significant disability/incapacity;congenital anomaly.Solicited AEs collected by semi-structured neuropsychiatric AEs interview inquiring about AEs:delusions,hallucinations,paranoia,psychosis,mania,panic,agitation,hostility,aggression,homicidal ideation. If participant had positive response,investigator determined if it met AE criteria.

    Time frame: Baseline up to Week 16

  2. Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement from baseline is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52

  3. Number of Participants With Clinical Global Impression - Severity (CGI-S) Score

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52

  4. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score

    Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Change: mean score at observation minus mean score at baseline.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16

  5. Change From Baseline in Hamilton Anxiety Scale (HAM-A) - Total Score

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. Change: mean score at observation minus mean score at baseline.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16

  6. Change From Baseline in Barratt Impulsiveness Scale (BIS-11) - Total Score

    The BIS-11 is a self-administered 30 items questionnaire to assess measure of impulsivity. Items are scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). Total score range from 30 to 120. Barratt suggested that a total score of greater than or equal to 75 could indicate an impulse-control disorder, whereas a total score in the range of 70 to 75 could indicate pathological impulsivity.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16

  7. Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS assessed if participant experienced following: completed suicide (1), suicide attempt (2)(response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4)("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Baseline, Week 1 up to 30 days after Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (follow-up [FU])

07

Results

Posted Apr 16, 2013

Participant flow

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started256269
Completed175179
Not completed8190
Withdrew: Lost to follow-up1213
Withdrew: Withdrawal by subject3133
Withdrew: Protocol violation66
Withdrew: Adverse event65
Withdrew: Death20
Withdrew: Did not meet entrance criteria01
Withdrew: Other2432

Outcome measures

PrimaryPercentage of Participants With a Four-Week Continuous Quit Rate (CQR)

Percentage of participants who reported no use of nicotine-containing products by answering "No" to the nicotine use inventory (NUI) questions: 'Has the participant smoked cigarettes' and 'Has the participant used other nicotine-containing products' in the last 7 days (Week 9) or since last study visit (Week 9 through 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm).

Time frame:
Week 9 through Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With a Four-Week Continuous Quit Rate (CQR)
Percentage of participantsVareniclinePlacebo
Percentage of Participants With a Four-Week Continuous Quit Rate (CQR)35.915.6
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.35 · 95% CI 2.16 to 5.21
SecondaryPercentage of Participants With Continuous Abstinence Rate (CAR)

Percentage of participants who remained abstinent from the period defined as start of the primary endpoint (Week 9) through Week 24 and the end of follow-up (Week 52) by reporting no use of nicotine-containing products confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

Time frame:
Week 9 through Week 24, Week 9 through Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Continuous Abstinence Rate (CAR)
Percentage of participantsVareniclinePlacebo
Week 9 through Week 2425.012.3
Week 9 through Week 5220.310.4
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = 0.0001 · Odds ratio (or): 2.53 · 95% CI 1.56 to 4.10
  • Varenicline vs Placebo · Regression, Logistic · p = 0.0011 · Odds ratio (or): 2.36 · 95% CI 1.40 to 3.98
SecondaryNumber of Participants With 7-day Point Prevalence (PP) of Abstinence

Number of participants reporting no use of nicotine-containing products in the last 7 days confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

Time frame:
Weeks 12, 24, 52
Reported as:
Number · participants
Number of Participants With 7-day Point Prevalence (PP) of Abstinence
participantsVareniclinePlacebo
Week 1211854
Week 248049
Week 527347
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.82 · 95% CI 2.53 to 5.78
  • Varenicline vs Placebo · Regression, Logistic · p = 0.0004 · Odds ratio (or): 2.16 · 95% CI 1.40 to 3.33
  • Varenicline vs Placebo · Regression, Logistic · p = 0.0020 · Odds ratio (or): 1.98 · 95% CI 1.28 to 3.08
SecondaryNumber of Participants With 4-Week Point Prevalence (PP) of Abstinence

Number of participants at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks confirmed by a measurement of an end-expiratory exhaled CO measurement less than or equal to 10 ppm.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants With 4-Week Point Prevalence (PP) of Abstinence
participantsVareniclinePlacebo
Number of Participants With 4-Week Point Prevalence (PP) of Abstinence7045
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = 0.0027 · Odds ratio (or): 1.97 · 95% CI 1.26 to 3.08
Other pre-specifiedNumber of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events)

Adverse Event (AE):any untoward medical occurrence attributed to study drug in participant who received study drug.SAE:AE causing:death;initial/prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying);persistent/significant disability/incapacity;congenital anomaly.Solicited AEs collected by semi-structured neuropsychiatric AEs interview inquiring about AEs:delusions,hallucinations,paranoia,psychosis,mania,panic,agitation,hostility,aggression,homicidal ideation. If participant had positive response,investigator determined if it met AE criteria.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events)
participantsVareniclinePlacebo
Number of Participants With Adverse Events (Including Solicited Neuropsychiatric Adverse Events)185180
Other pre-specifiedNumber of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement from baseline is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52
Reported as:
Number · participants
Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
participantsVareniclinePlacebo
Week 1: very much improved(n=250,263)12
Week 1: much improved(n=250,263)126
Week 1: minimally improved(n=250,263)3121
Week 1: no change(n=250,263)189222
Week 1: minimally worse(n=250,263)1611
Week 1: much worse(n=250,263)11
Week 2: very much improved(n=244,255)21
Week 2: much improved(n=244,255)1812
Week 2: minimally improved(n=244,255)3338
Week 2: no change(n=244,255)159181
Week 2: minimally worse(n=244,255)2721
Week 2: much worse(n=244,255)52
Week 3: very much improved(n=241,248)104
Week 3: much improved(n=241,248)1714
Week 3: minimally improved(n=241,248)4245
Week 3: no change(n=241,248)146165
Week 3: minimally worse(n=241,248)2617
Week 3: much worse(n=241,248)03
Week 4: very much improved(n=230,245)86
Week 4: much improved(n=230,245)1812
Week 4: minimally improved(n=230,245)3551
Week 4: no change(n=230,245)152154
Week 4: minimally worse(n=230,245)1519
Week 4: much worse(n=230,245)23
Week 5: very much improved(n=227,233)139
Week 5: much improved(n=227,233)1411
Week 5: minimally improved(n=227,233)3446
Week 5: no change(n=227,233)146151
Week 5: minimally worse(n=227,233)1914
Week 5: much worse(n=227,233)12
Week 6: very much improved(n=224,226)116
Week 6: much improved(n=224,226)2014
Week 6: minimally improved(n=224,226)3941
Week 6: no change(n=224,226)139148
Week 6: minimally worse(n=224,226)1317
Week 6: much worse(n=224,226)20
Week 7: very much improved(n=226,226)199
Week 7: much improved(n=226,226)2318
Week 7: minimally improved(n=226,226)3234
Week 7: no change(n=226,226)136150
Week 7: minimally worse(n=226,226)1413
Week 7: much worse(n=226,226)22
Week 8: very much improved(n=221,217)1912
Week 8: much improved(n=221,217)1815
Week 8: minimally improved(n=221,217)3740
Week 8: no change(n=221,217)131139
Week 8: minimally worse(n=221,217)1510
Week 8: much worse(n=221,217)01
Week 8: very much worse(n=221,217)10
Week 9: very much improved(n=218,214)1913
Week 9: much improved(n=218,214)1916
Week 9: minimally improved(n=218,214)3631
Week 9: no change(n=218,214)129141
Week 9: minimally worse(n=218,214)1513
Week 10: very much improved(n=212,211)2013
Week 10: much improved(n=212,211)2118
Week 10: minimally improved(n=212,211)3035
Week 10: no change(n=212,211)124133
Week 10: minimally worse(n=212,211)1611
Week 10: much worse(n=212,211)11
Week 11: very much improved(n=211,205)2315
Week 11: much improved(n=211,205)1714
Week 11: minimally improved(n=211,205)3835
Week 11: no change(n=211,205)120129
Week 11: minimally worse(n=211,205)1310
Week 11: much worse(n=211,205)02
Week 12: very much improved(n=210,204)1917
Week 12: much improved(n=210,204)1913
Week 12: minimally improved(n=210,204)3439
Week 12: no change(n=210,204)127124
Week 12: minimally worse(n=210,204)1111
Week 13: very much improved(n=211,200)1816
Week 13: much improved(n=211,200)1913
Week 13: minimally improved(n=211,200)3440
Week 13: no change(n=211,200)127121
Week 13: minimally worse(n=211,200)1210
Week 13: much worse(n=211,200)10
Week 16: very much improved(n=203,199)1715
Week 16: much improved(n=203,199)2716
Week 16: minimally improved(n=203,199)2633
Week 16: no change(n=203,199)119119
Week 16: minimally worse(n=203,199)1412
Week 16: much worse(n=203,199)04
Week 24: very much improved(n=196,193)1713
Week 24: much improved(n=196,193)1718
Week 24: minimally improved(n=196,193)2431
Week 24: no change(n=196,193)127125
Week 24: minimally worse(n=196,193)106
Week 24: much worse(n=196,193)10
Week 32: very much improved(n=188,188)1519
Week 32: much improved(n=188,188)1921
Week 32: minimally improved(n=188,188)2731
Week 32: no change(n=188,188)118113
Week 32: minimally worse(n=188,188)93
Week 32: much worse(n=188,188)01
Week 40: very much improved(n=180,182)1017
Week 40: much improved(n=180,182)2315
Week 40: minimally improved(n=180,182)2332
Week 40: no change(n=180,182)117109
Week 40: minimally worse(n=180,182)67
Week 40: much worse(n=180,182)02
Week 40: very much worse(n=180,182)10
Week 52: very much improved(n=178,180)2022
Week 52: much improved(n=178,180)2013
Week 52: minimally improved(n=178,180)2526
Week 52: no change(n=178,180)110112
Week 52: minimally worse(n=178,180)37
Other pre-specifiedNumber of Participants With Clinical Global Impression - Severity (CGI-S) Score

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 24, 32, 40, 52
Reported as:
Number · participants
Number of Participants With Clinical Global Impression - Severity (CGI-S) Score
participantsVareniclinePlacebo
Baseline:Normal; Week 1:Normal (n=250,263)105100
Baseline:Borderline; Week 1:Normal (n=250,263)78
Baseline:Mildly; Week 1:Normal (n=250,263)41
Baseline:Moderately; Week 1:Normal (n=250,263)10
Baseline:Normal; Week 1:Borderline (n=250,263)33
Baseline:Borderline; Week 1:Borderline (n=250,263)3142
Baseline:Mildly; Week 1:Borderline (n=250,263)93
Baseline:Moderately; Week 1:Borderline (n=250,263)23
Baseline:Normal; Week 1:Mildly (n=250,263)02
Baseline:Borderline; Week 1:Mildly (n=250,263)41
Baseline:Mildly; Week 1:Mildly (n=250,263)4656
Baseline:Moderately; Week 1:Mildly (n=250,263)69
Baseline:Borderline; Week 1:Moderately (n=250,263)12
Baseline:Mildly; Week 1:Moderately (n=250,263)10
Baseline:Moderately; Week 1:Moderately (n=250,263)2830
Baseline:Markedly; Week 1:Moderately (n=250,263)10
Baseline:Markedly; Week 1:Markedly (n=250,263)13
Baseline:Normal; Week 2:Normal (n=244,254)10296
Baseline:Borderline; Week 2:Normal (n=244,254)1312
Baseline:Mildly; Week 2:Normal (n=244,254)50
Baseline: Moderately; Week 2:Normal (n=244,254)01
Baseline:Normal; Week 2:Borderline (n=244,254)15
Baseline:Borderline; Week 2:Borderline (n=244,254)2237
Baseline:Mildly; Week 2:Borderline (n=244,254)107
Baseline:Moderately; Week 2:Borderline (n=244,254)44
Baseline:Normal; Week 2:Mildly (n=244,254)32
Baseline:Borderline; Week 2:Mildly (n=244,254)40
Baseline:Mildly; Week 2:Mildly (n=244,254)4048
Baseline:Moderately; Week 2:Mildly (n=244,254)1012
Baseline:Markedly; Week 2:Mildly (n=244,254)10
Baseline:Normal; Week 2:Moderately (n=244,254)20
Baseline:Borderline; Week 2:Moderately (n=244,254)11
Baseline:Mildly; Week 2:Moderately (n=244,254)22
Baseline:Moderately; Week 2:Moderately (n=244,254)2024
Baseline:Markedly; Week 2:Moderately (n=244,254)01
Baseline: Moderately; Week 2:Markedly (n=244,254)30
Baseline:Markedly; Week 2:Markedly (n=244,254)12
Baseline:Normal; Week 3:Normal (n=241,247)10195
Baseline:Borderline; Week 3:Normal (n=241,247)1816
Baseline:Mildly; Week 3:Normal (n=241,247)64
Baseline:Moderately; Week 3:Normal (n=241,247)20
Baseline:Normal; Week 3:Borderline (n=241,247)32
Baseline:Borderline; Week 3:Borderline (n=241,247)1634
Baseline:Mildly; Week 3:Borderline (n=241,247)87
Baseline:Moderately; Week 3:Borderline (n=241,247)42
Baseline:Normal; Week 3:Mildly (n=241,247)20
Baseline:Borderline; Week 3:Mildly (n=241,247)62
Baseline:Mildly; Week 3:Mildly (n=241,247)4242
Baseline:Moderately; Week 3:Mildly (n=241,247)1017
Baseline:Markedly; Week 3:Mildly (n=241,247)10
Baseline:Normal; Week 3:Moderately (n=241,247)02
Baseline:Mildly; Week 3:Moderately (n=241,247)21
Baseline:Moderately; Week 3:Moderately (n=241,247)1920
Baseline:Markedly; Week 3:Moderately (n=241,247)01
Baseline:Moderately; Week 3:Markedly (n=241,247)01
Baseline:Markedly; Week 3:Markedly (n=241,247)11
Baseline:Normal; Week 4:Normal (n=230,244)10192
Baseline:Borderline; Week 4:Normal (n=230,244)1717
Baseline:Mildly; Week 4:Normal (n=230,244)75
Baseline:Moderately; Week 4:Normal (n=230,244)41
Baseline:Normal; Week 4:Borderline (n=230,244)25
Baseline:Borderline; Week 4:Borderline (n=230,244)1727
Baseline:Mildly; Week 4:Borderline (n=230,244)87
Baseline:Moderately; Week 4:Borderline (n=230,244)13
Baseline:Normal; Week 4:Mildly (n=230,244)02
Baseline:Borderline; Week 4:Mildly (n=230,244)32
Baseline:Mildly; Week 4:Mildly (n=230,244)3943
Baseline:Moderately; Week 4:Mildly (n=230,244)1115
Baseline:Markedly; Week 4:Mildly (n=230,244)11
Baseline:Borderline; Week 4:Moderately (n=230,244)20
Baseline:Mildly; Week 4:Moderately (n=230,244)22
Baseline:Moderately; Week 4:Moderately (n=230,244)122
Baseline:Markedly; Week 4:Moderately (n=230,244)118
Baseline:Borderline; Week 4:Markedly (n=230,244)10
Baseline:Moderately; Week 4:Markedly (n=230,244)10
Baseline:Markedly; Week 4:Markedly (n=230,244)02
Baseline:Normal; Week 5:Normal (n=227,232)9888
Baseline:Borderline; Week 5:Normal (n=227,232)1916
Baseline:Mildly; Week 5:Normal (n=227,232)86
Baseline:Moderately; Week 5:Normal (n=227,232)44
Baseline:Normal; Week 5:Borderline (n=227,232)21
Baseline:Borderline; Week 5:Borderline (n=227,232)1330
Baseline:Mildly; Week 5:Borderline (n=227,232)84
Baseline:Moderately; Week 5:Borderline (n=227,232)23
Baseline:Normal; Week 5:Mildly (n=227,232)21
Baseline:Borderline; Week 5:Mildly (n=227,232)62
Baseline:Mildly; Week 5:Mildly (n=227,232)3639
Baseline:Moderately; Week 5:Mildly (n=227,232)1115
Baseline:Markedly; Week 5:Mildly (n=227,232)21
Baseline:Normal; Week 5:Moderately (n=227,232)01
Baseline:Borderline; Week 5:Moderately (n=227,232)10
Baseline:Mildly; Week 5:Moderately (n=227,232)24
Baseline:Moderately; Week 5:Moderately (n=227,232)1215
Baseline:Markedly; Week 5:Moderately (n=227,232)01
Baseline:Moderately; Week 5:Markedly (n=227,232)11
Baseline:Normal; Week 6:Normal (n=224,225)9684
Baseline:Borderline; Week 6:Normal (n=224,225)2218
Baseline:Mildly; Week 6:Normal (n=224,225)104
Baseline:Moderately; Week 6:Normal (n=224,225)31
Baseline:Normal; Week 6:Borderline (n=224,225)33
Baseline:Borderline; Week 6:Borderline (n=224,225)1124
Baseline:Mildly; Week 6:Borderline (n=224,225)67
Baseline:Moderately; Week 6:Borderline (n=224,225)54
Baseline:Normal; Week 6:Mildly (n=224,225)22
Baseline:Borderline; Week 6:Mildly (n=224,225)52
Baseline:Mildly; Week 6:Mildly (n=224,225)3837
Baseline:Moderately; Week 6:Mildly (n=224,225)815
Baseline:Markedly; Week 6:Mildly (n=224,225)21
Baseline:Normal; Week 6:Moderately (n=224,225)03
Baseline:Borderline; Week 6:Moderately (n=224,225)11
Baseline:Mildly; Week 6:Moderately (n=224,225)13
Baseline:Moderately; Week 6:Moderately (n=224,225)1014
Baseline:Moderately; Week 6:Markedly (n=224,225)11
Baseline:Markedly; Week 6:Markedly (n=224,225)01
Baseline:Normal; Week 7:Normal (n=226,225)9388
Baseline:Borderline; Week 7:Normal (n=226,225)2320
Baseline:Mildly; Week 7:Normal (n=226,225)145
Baseline:Moderately; Week 7:Normal (n=226,225)31
Baseline:Normal; Week 7:Borderline (n=226,225)52
Baseline:Borderline; Week 7:Borderline (n=226,225)1323
Baseline:Mildly; Week 7:Borderline (n=226,225)46
Baseline:Moderately; Week 7:Borderline (n=226,225)58
Baseline:Markedly; Week 7:Borderline (n=226,225)10
Baseline:Normal; Week 7:Mildly (n=226,225)20
Baseline:Borderline; Week 7:Mildly (n=226,225)22
Baseline:Mildly; Week 7:Mildly (n=226,225)3637
Baseline:Moderately; Week 7:Mildly (n=226,225)1010
Baseline:Markedly; Week 7:Mildly (n=226,225)11
Baseline:Normal; Week 7:Moderately (n=226,225)01
Baseline:Borderline; Week 7:Moderately (n=226,225)11
Baseline:Mildly; Week 7:Moderately (n=226,225)24
Baseline:Moderately; Week 7:Moderately (n=226,225)1014
Baseline:Markedly; Week 7:Moderately (n=226,225)01
Baseline:Moderately; Week 7:Markedly (n=226,225)11
Baseline:Normal; Week 8:Normal (n=221,216)9287
Baseline:Borderline; Week 8:Normal (n=221,216)2119
Baseline:Mildly; Week 8:Normal (n=221,216)126
Baseline:Moderately; Week 8:Normal (n=221,216)33
Baseline:Normal; Week 8:Borderline (n=221,216)42
Baseline:Borderline; Week 8:Borderline (n=221,216)1419
Baseline:Mildly; Week 8:Borderline (n=221,216)67
Baseline:Moderately; Week 8:Borderline (n=221,216)75
Baseline:Markedly; Week 8:Borderline (n=221,216)20
Baseline:Normal; Week 8:Mildly (n=221,216)20
Baseline:Borderline; Week 8:Mildly (n=221,216)32
Baseline:Mildly; Week 8:Mildly (n=221,216)3235
Baseline:Moderately; Week 8:Mildly (n=221,216)913
Baseline:Markedly; Week 8:Mildly (n=221,216)01
Baseline:Normal; Week 8:Moderately (n=221,216)10
Baseline:Mildly; Week 8:Moderately (n=221,216)33
Baseline:Moderately; Week 8:Moderately (n=221,216)912
Baseline:Markedly; Week 8:Moderately (n=221,216)01
Baseline:Mildly; Week 8:Markedly (n=221,216)01
Baseline:Moderately; Week 8:Markedly (n=221,216)10
Baseline:Normal; Week 9:Normal (n=218,213)9187
Baseline:Borderline; Week 9:Normal (n=218,213)2218
Baseline:Mildly; Week 9:Normal (n=218,213)115
Baseline:Moderately; Week 9:Normal (n=218,213)44
Baseline:Normal; Week 9:Borderline (n=218,213)32
Baseline:Borderline; Week 9:Borderline (n=218,213)1319
Baseline:Mildly; Week 9:Borderline (n=218,213)63
Baseline:Moderately; Week 9:Borderline (n=218,213)68
Baseline:Markedly; Week 9:Borderline (n=218,213)21
Baseline:Normal; Week 9:Mildly (n=218,213)30
Baseline:Borderline; Week 9:Mildly (n=218,213)24
Baseline:Mildly; Week 9:Mildly (n=218,213)3438
Baseline:Moderately; Week 9:Mildly (n=218,213)109
Baseline:Mildly; Week 9:Moderately (n=218,213)10
Baseline:Moderately; Week 9:Moderately (n=218,213)812
Baseline:Markedly; Week 9:Moderately (n=218,213)01
Baseline:Mildly; Week 9:Markedly (n=218,213)11
Baseline:Moderately; Week 9:Markedly (n=218,213)11
Baseline:Normal; Week 10:Normal (n=212,210)8885
Baseline:Borderline; Week 10:Normal (n=212,210)2021
Baseline:Mildly; Week 10:Normal (n=212,210)135
Baseline:Moderately; Week 10:Normal (n=212,210)75
Baseline:Normal; Week 10:Borderline (n=212,210)51
Baseline:Borderline; Week 10:Borderline (n=212,2101418
Baseline:Mildly; Week 10:Borderline (n=212,210)66
Baseline:Moderately; Week 10:Borderline(n=212,210)47
Baseline:Markedly; Week 10:Borderline(n=212,210)21
Baseline:Normal; Week 10:Mildly (n=212,210)11
Baseline:Borderline; Week 10:Mildly (n=212,210)12
Baseline:Mildly; Week 10:Mildly (n=212,210)2935
Baseline:Moderately; Week 10:Mildly (n=212,210)811
Baseline:Normal; Week 10:Moderately (n=212,210)10
Baseline:Mildly; Week 10:Moderately (n=212,210)31
Baseline:Moderately; Week 10:Moderately(n=212,210)99
Baseline:Markedly; Week 10:Moderately (n=212,210)01
Baseline:Moderately; Week 10:Markedly (n=212,210)11
Baseline:Normal; Week 11:Normal (n=211,205)9081
Baseline:Borderline; Week 11:Normal (n=211,205)2322
Baseline:Mildly; Week 11:Normal (n=211,205)136
Baseline:Moderately; Week 11:Normal (n=211,205)75
Baseline:Markedly; Week 11:Normal (n=211,205)10
Baseline:Normal; Week 11:Borderline (n=211,205)32
Baseline:Borderline; Week 11:Borderline(n=211,205)1015
Baseline:Mildly; Week 11:Borderline (n=211,205)63
Baseline:Moderately; Week 11:Borderline(n=211,205)36
Baseline:Markedly; Week 11:Borderline (n=211,205)11
Baseline:Normal; Week 11:Mildly (n=211,205)10
Baseline:Borderline; Week 11:Mildly (n=211,205)23
Baseline:Mildly; Week 11:Mildly (n=211,205)3034
Baseline:Moderately; Week 11:Mildly (n=211,205)913
Baseline:Normal; Week 11:Moderately (n=211,205)01
Baseline:Mildly; Week 11:Moderately (n=211,205)31
Baseline:Moderately; Week 11:Moderately(n=211,205)810
Baseline:Markedly; Week 11:Moderately (n=211,205)01
Baseline:Mildly; Week 11:Markedly (n=211,205)01
Baseline:Normal; Week 12:Normal (n=210,203)8979
Baseline:Borderline; Week 12:Normal (n=210,203)2322
Baseline:Mildly; Week 12:Normal (n=210,203)136
Baseline:Moderately; Week 12:Normal (n=210,203)68
Baseline:Markedly; Week 12:Normal (n=210,203)10
Baseline:Normal; Week 12:Borderline (n=210,203)42
Baseline:Borderline; Week 12:Borderline(n=210,203)1216
Baseline:Mildly; Week 12:Borderline (n=210,203)64
Baseline:Moderately; Week 12:Borderline(n=210,203)43
Baseline:Markedly; Week 12:Borderline (n=210,203)11
Baseline:Normal; Week 12:Mildly (n=210,203)02
Baseline:Borderline; Week 12:Mildly (n=210,203)01
Baseline:Mildly; Week 12:Mildly (n=210,203)3034
Baseline:Moderately; Week 12:Mildly (n=210,203)914
Baseline:Borderline; Week 12:Moderately(n=210,203)01
Baseline:Mildly; Week 12:Moderately (n=210,203)33
Baseline:Moderately; Week 12:Moderately(n=210,203)86
Baseline:Markedly; Week 12:Moderately(n=210,203)01
Baseline:Moderately; Week 12:Markedly(n=210,203)10
Baseline:Normal; Week 13:Normal (n=211,199)9278
Baseline:Borderline; Week 13:Normal (n=211,199)2221
Baseline:Mildly; Week 13:Normal (n=211,199)135
Baseline:Moderately; Week 13:Normal (n=211,199)69
Baseline:Markedly; Week 13:Normal (n=211,199)20
Baseline:Normal; Week 13:Borderline (n=211,199)33
Baseline:Borderline; Week 13:Borderline(n=211,199)1117
Baseline:Mildly; Week 13:Borderline (n=211,199)76
Baseline:Moderately; Week 13:Borderline(n=211,199)54
Baseline:Markedly; Week 13:Borderline(n=211,199)01
Baseline:Borderline; Week 13:Mildly (n=211,199)03
Baseline:Mildly; Week 13:Mildly (n=211,199)3032
Baseline:Moderately; Week 13:Mildly (n=211,199)911
Baseline:Mildly; Week 13:Moderately (n=211,199)31
Baseline:Moderately; Week 13:Moderately(n=211,199)77
Baseline:Markedly; Week 13:Moderately(n=211,199)01
Baseline:Moderately; Week 13:Markedly (n=211,199)10
Baseline:Normal; Week 16:Normal (n=203,198)9178
Baseline:Borderline; Week 16:Normal (n=203,198)1920
Baseline:Mildly; Week 16:Normal (n=203,198)146
Baseline:Moderately; Week 16:Normal (n=203,198)711
Baseline:Markedly; Week 16:Normal (n=203,198)20
Baseline:Normal; Week 16:Borderline (n=203,198)22
Baseline:Borderline; Week 16:Borderline(n=203,198)1116
Baseline:Mildly; Week 16:Borderline (n=203,198)45
Baseline:Moderately; Week 16:Borderline(n=203,198)22
Baseline:Markedly; Week 16:Borderline (n=203,198)01
Baseline:Normal; Week 16:Mildly (n=203,198)12
Baseline:Borderline; Week 16:Mildly (n=203,198)03
Baseline:Mildly; Week 16:Mildly (n=203,198)3030
Baseline:Moderately; Week 16:Mildly (n=203,198)118
Baseline:Borderline; Week 16:Moderately(n=203,198)02
Baseline:Mildly; Week 16:Moderately (n=203,198)32
Baseline:Moderately; Week 16:Moderately(n=203,198)48
Baseline:Markedly; Week 16:Moderately (n=203,198)01
Baseline:Moderately; Week 16:Markedly (n=203,198)21
Baseline:Normal; Week 24:Normal (n=196,192)8878
Baseline:Borderline; Week 24:Normal (n=196,192)1819
Baseline:Mildly; Week 24:Normal (n=196,192)156
Baseline:Moderately; Week 24:Normal (n=196,192)58
Baseline:Markedly; Week 24:Normal (n=196,192)20
Baseline:Normal; Week 24:Borderline (n=196,192)03
Baseline:Borderline; Week 24:Borderline(n=196,192)1314
Baseline:Mildly; Week 24:Borderline (n=196,192)46
Baseline:Moderately; Week 24:Borderline(n=196,192)22
Baseline:Markedly; Week 24:Borderline (n=196,192)01
Baseline:Normal; Week 24:Mildly (n=196,192)21
Baseline:Borderline; Week 24:Mildly (n=196,192)03
Baseline:Mildly; Week 24:Mildly (n=196,192)2731
Baseline:Moderately; Week 24:Mildly (n=196,192)812
Baseline:Mildly; Week 24:Moderately (n=196,192)40
Baseline:Moderately; Week 24:Moderately(n=196,192)77
Baseline:Markedly; Week 24:Moderately (n=196,192)01
Baseline:Moderately; Week 24:Markedly (n=196,192)10
Baseline:Normal; Week 32:Normal (n=188,187)8277
Baseline:Borderline; Week 32:Normal (n=188,187)1620
Baseline:Mildly; Week 32:Normal (n=188,187)108
Baseline:Moderately; Week 32:Normal (n=188,187)49
Baseline:Markedly; Week 32:Normal (n=188,187)20
Baseline:Normal; Week 32:Borderline (n=188,187)01
Baseline:Borderline; Week 32:Borderline(n=188,187)1215
Baseline:Mildly; Week 32:Borderline (n=188,187)97
Baseline:Moderately; Week 32:Borderline(n=188,187)41
Baseline:Markedly; Week 32:Borderline (n=188,187)01
Baseline:Normal; Week 32:Mildly (n=188,187)20
Baseline:Borderline; Week 32:Mildly (n=188,187)01
Baseline:Mildly; Week 32:Mildly (n=188,187)2829
Baseline:Moderately; Week 32:Mildly (n=188,187)811
Baseline:Markedly; Week 32:Mildly (n=188,187)01
Baseline:Mildly; Week 32:Moderately (n=188,187)30
Baseline:Moderately; Week 32:Moderately(n=188,187)75
Baseline:Borderline; Week 32:Markedly (n=188,187)01
Baseline:Moderately; Week 32:Markedly (n=188,187)10
Baseline:Normal; Week 40:Normal (n=180,181)8171
Baseline:Borderline; Week 40:Normal (n=180,181)1720
Baseline:Mildly; Week 40:Normal (n=180,181)117
Baseline:Moderately; Week 40:Normal (n=180,181)27
Baseline:Markedly; Week 40:Normal (n=180,181)20
Baseline:Normal; Week 40:Borderline (n=180,181)02
Baseline:Borderline; Week 40:Borderline(n=180,181)915
Baseline:Mildly; Week 40:Borderline (n=180,181)86
Baseline:Moderately; Week 40:Borderline(n=180,181)42
Baseline:Markedly; Week 40:Borderline (n=180,181)01
Baseline:Normal; Week 40:Mildly (n=180,181)10
Baseline:Borderline; Week 40:Mildly (n=180,181)22
Baseline:Mildly; Week 40:Mildly (n=180,181)2528
Baseline:Moderately; Week 40:Mildly (n=180,181)1112
Baseline:Markedly; Week 40:Mildly (n=180,181)01
Baseline:Normal; Week 40:Moderately (n=180,181)01
Baseline:Mildly; Week 40:Moderately (n=180,181)21
Baseline:Moderately; Week 40:Moderately(n=180,181)43
Baseline:Moderately; Week 40:Markedly (n=180,181)12
Baseline:Normal; Week 52:Normal (n=178,179)8169
Baseline:Borderline; Week 52:Normal (n=178,179)1920
Baseline:Mildly; Week 52:Normal (n=178,179)127
Baseline:Moderately; Week 52:Normal (n=178,179)47
Baseline:Markedly; Week 52:Normal (n=178,179)20
Baseline:Normal; Week 52:Borderline (n=178,179)14
Baseline:Borderline; Week 52:Borderline(n=178,179)814
Baseline:Mildly; Week 52:Borderline (n=178,179)88
Baseline:Moderately; Week 52:Borderline(n=178,179)44
Baseline:Markedly; Week 52:Borderline (n=178,179)01
Baseline:Normal; Week 52:Mildly (n=178,179)10
Baseline:Borderline; Week 52:Mildly (n=178,179)02
Baseline:Mildly; Week 52:Mildly (n=178,179)2426
Baseline:Moderately; Week 52:Mildly (n=178,179)811
Baseline:Mildly; Week 52:Moderately (n=178,179)11
Baseline:Moderately; Week 52:Moderately(n=178,179)44
Baseline:Markedly; Week 52:Moderately (n=178,179)01
Baseline:Moderately; Week 52:Markedly (n=178,179)10
Other pre-specifiedChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score

Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Change: mean score at observation minus mean score at baseline.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score
Units on a scaleVareniclinePlacebo
Baseline(n=256,269)7.6 ± 7.387.9 ± 7.51
Change at Week 1(n=250,265)-1.2 ± 3.95-0.6 ± 4.17
Change at Week 2(n= 245, 255)-1.0 ± 6.06-1.1 ± 5.33
Change at Week 3(n= 241, 249)-1.9 ± 5.19-1.8 ± 4.96
Change at Week 4(n= 230, 246)-2.2 ± 5.62-1.5 ± 5.96
Change at Week 5(n=228, 235)-2.1 ± 6.01-2.3 ± 6.09
Change at Week 6(n=224, 227)-2.2 ± 6.15-2.3 ± 5.84
Change at Week 7(n=226, 227)-2.3 ± 6.57-2.4 ± 5.94
Change at Week 8(n=221, 218)-2.7 ± 6.51-2.6 ± 6.02
Change at Week 9(n=218, 216)-2.9 ± 6.11-2.5 ± 6.55
Change at Week 10(n=214, 212)-2.9 ± 6.21-2.8 ± 6.15
Change at Week 11(n= 211, 206)-3.2 ± 6.30-2.9 ± 6.13
Change at Week 12(n= 210, 205)-3.4 ± 6.20-3.2 ± 6.34
Change at Week 13(n= 211, 201)-3.0 ± 6.39-3.6 ± 5.88
Change at Week 16(n= 202, 197)-3.1 ± 6.36-3.2 ± 6.61
Other pre-specifiedChange From Baseline in Hamilton Anxiety Scale (HAM-A) - Total Score

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. Change: mean score at observation minus mean score at baseline.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Reported as:
Mean · Units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) - Total Score
Units on a scaleVareniclinePlacebo
Baseline(n=256,269)6.1 ± 5.236.4 ± 5.17
Change at Week 1(n=250,265)-0.5 ± 2.54-0.7 ± 3.15
Change at Week 2(n= 245, 255)-0.7 ± 3.98-0.5 ± 3.79
Change at Week 3(n= 241, 249)-1.3 ± 3.41-1.2 ± 3.68
Change at Week 4(n= 230, 246)-1.6 ± 3.72-1.2 ± 3.87
Change at Week 5(n=228, 235)-1.6 ± 4.05-1.6 ± 4.00
Change at Week 6(n=224, 227)-1.7 ± 4.03-1.6 ± 4.00
Change at Week 7(n=226, 227)-2.0 ± 4.40-1.8 ± 4.32
Change at Week 8(n=221, 218)-1.9 ± 4.65-1.9 ± 4.10
Change at Week 9(n=218, 216)-2.0 ± 4.40-1.9 ± 3.94
Change at Week 10(n=214, 212)-2.2 ± 4.24-2.0 ± 4.12
Change at Week 11(n= 211, 206)-2.3 ± 4.48-2.1 ± 4.31
Change at Week 12(n= 210, 205)-2.3 ± 4.27-2.4 ± 4.47
Change at Week 13(n= 211, 201)-2.4 ± 4.49-2.7 ± 4.34
Change at Week 16(n= 202, 197)-2.7 ± 4.67-2.5 ± 4.28
Other pre-specifiedChange From Baseline in Barratt Impulsiveness Scale (BIS-11) - Total Score

The BIS-11 is a self-administered 30 items questionnaire to assess measure of impulsivity. Items are scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). Total score range from 30 to 120. Barratt suggested that a total score of greater than or equal to 75 could indicate an impulse-control disorder, whereas a total score in the range of 70 to 75 could indicate pathological impulsivity.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16
Reported as:
Mean · Units on a scale
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) - Total Score
Units on a scaleVareniclinePlacebo
Baseline(n=256,269)65.1 ± 6.4264.2 ± 7.30
Change at Week 1(n=250,265)-0.5 ± 4.36-0.8 ± 4.26
Change at Week 2(n= 244, 255)-0.8 ± 4.73-1.1 ± 4.83
Change at Week 3(n= 241, 249)-1.0 ± 4.75-1.3 ± 4.81
Change at Week 4(n= 230, 246)-1.0 ± 5.19-1.2 ± 4.95
Change at Week 5(n=228, 234)-1.1 ± 5.27-1.1 ± 5.39
Change at Week 6(n=224, 226)-1.4 ± 5.28-1.2 ± 5.43
Change at Week 7(n=226, 227)-1.6 ± 5.62-1.3 ± 6.08
Change at Week 8(n=219, 216)-1.3 ± 5.81-1.2 ± 6.54
Change at Week 9(n=218, 215)-1.5 ± 6.25-1.4 ± 6.24
Change at Week 10(n=214, 211)-1.5 ± 6.13-1.7 ± 6.94
Change at Week 11(n= 211, 205)-1.6 ± 6.24-1.5 ± 6.78
Change at Week 12(n= 210, 204)-1.0 ± 6.55-1.4 ± 7.31
Change at Week 13(n= 211, 201)-1.4 ± 6.52-1.1 ± 7.00
Change at Week 16(n= 202, 196)-1.4 ± 6.25-1.3 ± 6.85
Other pre-specifiedNumber of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS assessed if participant experienced following: completed suicide (1), suicide attempt (2)(response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4)("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").

Time frame:
Baseline, Week 1 up to 30 days after Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (follow-up [FU])
Reported as:
Number · participants
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
participantsVareniclinePlacebo
Baseline,Suicidal Behavior or/and Ideation61
Baseline,461
Baseline,4: wish to be dead61
TE,Suicidal Behavior or/and Ideation1520
TE,201
TE,41519
TE,4: wish to be dead1518
TE,4: non-specific active suicidal thoughts47
TE,4: with any methods,without intent to act25
TE,4: with some intent,without specific plan.03
TE,4: with specific plan and intent01
FU,Suicidal Behavior or/and Ideation1312
FU,110
FU,41212
FU,4: wish to be dead1112
FU,4: non-specific active suicidal thoughts53
FU,4: with any methods,without intent to act22
FU,4: with some intent,without specific plan11
FU,711

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—7/256 (2.7%)158/256 (61.7%)
Placebo—7/269 (2.6%)126/269 (46.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventVareniclinePlacebo
PalpitationsCardiac disorders1/2560/269
Acute abdomenGastrointestinal disorders1/2560/269
Autoimmune hepatitisHepatobiliary disorders1/2560/269
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2560/269
Ligament laxityMusculoskeletal and connective tissue disorders1/2560/269
Depression suicidalPsychiatric disorders1/2561/269
Intentional sefl-injuryPsychiatric disorders1/2561/269
Psychotic disorderPsychiatric disorders1/2560/269
Claculus uretericRenal and urinary disorders1/2560/269
Haemodynamic instabilityVascular disorders1/2560/269
Most frequent other events
Showing 10 of 15
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders69/25628/269
HeadacheNervous system disorders43/25630/269
Abnormal dreamsPsychiatric disorders29/25622/269
IrritabilityGeneral disorders28/25622/269
InsomniaPsychiatric disorders28/25613/269
AnxietyPsychiatric disorders18/25625/269
Dry mouthGastrointestinal disorders17/25614/269
AgitationPsychiatric disorders17/25610/269
DepressionPsychiatric disorders17/25613/269
DiarrhoeaGastrointestinal disorders16/25612/269

Baseline characteristics

Age, Customized
Age, Customized(participants)VareniclinePlaceboTotal
18 to 44 years10698204
45 to 64 years146160306
Greater than or equal to 65 years41115
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female159170329
Male9799196
08

Study locations

41 sites
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • California Neuroscience Research Medical Group, Inc
    Sherman Oaks, California 91403, United States
  • Behavioral Health and Wellness Program, University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • Emerald Coast Mood & Memory, PA
    Fort Walton Beach, Florida 32547, United States
  • Clinical Neuroscience Solutions Incorporated
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions Incorporated
    Orlando, Florida 32806, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Vince and Associates Clinical Research
    Overland, Kansas 66211, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • NorthCoast Clinical Trials Inc.
    Beachwood, Ohio 44122, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati
    Cincinnati, Ohio 45237, United States
  • CRI Worldwide LLC
    Philadelphia, Pennsylvania 19139, United States
  • Clinical Trials of Memphis
    Bartlett, Tennessee 38134, United States
  • FutureSearch Trials
    Austin, Texas 78731, United States
  • Claghorn-Lesem Research Clinic, Ltd.
    Houston, Texas 77008, United States
  • Psychiatric Clinic, Clinical Center Banja Luka
    Banja Luka, 78000, Bosnia and Herzegovina
  • Clinic of Psychiatry, Clinical Center University of Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • "Poliklinika Neuron" - Croatian Institute for Brain Research
    Zagreb, 10000, Croatia
  • Psychiatric Hospital Vrapce
    Zagreb, 10000, Croatia
  • Universitaetsklinikum Freiburg
    Freiburg, 79104, Germany
  • Ludwig Maximilians-Universitaet Muenchen
    Muenchen, 80336, Germany
  • Universitaetsklinik Tuebingen, Klinik fuer Psychiatrie und Psychotherapie
    Tuebingen, 72076, Germany
  • Fovarosi Onkormanyzat Nyiro Gyula Korhaz, II. Pszichiatriai Osztaly
    Budapest, 1135, Hungary
  • Processus Kft., Varoskapu Rendelo
    Budapest, 1137, Hungary
  • Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Pszichiatriai Osztaly
    Gyula, 5700, Hungary
  • Varosi Egeszsegugyi Kozpont
    Kunszentmarton, 5440, Hungary
  • Fejer Megyei Szent Gyorgy Korhaz, Pszichiatriai Osztaly
    Szekesfehervar, 8000, Hungary
  • Donatella 99 Bt.
    Szentes, 6600, Hungary
  • Spitalul Psihiatrie "Prof. Dr. Al. Obregia"
    Bucuresti, Sector 4, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Al. Obregia, sectia 2
    Bucuresti, 041902, Romania
  • Spitalul Clinic de Psihiatrie Socola, sectia VII
    Iasi, 700282, Romania
  • Federal State Institution Moscow Scientific Research Institute of Psychiatry of Roszdrav
    Moscow, 107076, Russian Federation
  • Institution of Russian Academy of Medical Sciences Mental Health Research Center
    Moscow, 115522, Russian Federation
  • Moscow State Healthcare Institution Clinical Mental Hospital No 12
    Moscow, 125367, Russian Federation
  • St-Petersburg State Healthcare Institution St. Nicholas Mental Hospital
    St-Petersburg, 190121, Russian Federation
  • Centro de Salud Mental Ii "La Corredoria"
    Oviedo, Asturias 33011, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital General de La Vall D'Hebron
    Barcelona, 08035, Spain
  • Centro de Salud Torrero La Paz
    Zaragoza, 50007, Spain
09

References and documents

Publications

  • Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, Yunis C. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013 Sep 17;159(6):390-400. doi: 10.7326/0003-4819-159-6-201309170-00005. Erratum In: Ann Intern Med. 2013 Oct 15;159(8):576. PubMed 24042367 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 2, 2010
Start
Mar 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Apr 16, 2013
Last update
Apr 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01078298
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
Mar 2010
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Apr 16, 2013
Last update
Apr 16, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion